Improved efficacy by individualized combination therapy with Peg IFN-α 2a and ADV in HBeAg positive chronic hepatitis B patients

Hepato-Gastroenterology

Volumn 59, Issue 115, 2012, Pages 680-686

  Wang, Ya Dong ^a   Zhao, Cai Yan ^a   Wang, Wei ^a   Shen, Chuan ^a   Lu, Hong Zhi ^a   Zhang, Li ^a   Yu, Wei Yan ^a   Zhou, Jun Ying ^a   Yan, Wen Zhao ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Adefovir dipivoxil; Chronic hepatitis B; Combination therapy; Pegylated interferon alpha

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; CREATINE KINASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LIOTHYRONINE; PEGINTERFERON ALPHA2A; TELBIVUDINE; THIAMAZOLE; THYROTROPIN; THYROXINE; VIRUS DNA;

ABDOMINAL DISCOMFORT; ADULT; AGED; ANEMIA; ANTIVIRAL THERAPY; APATHY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GRANULOCYTOPENIA; HAIR DISEASE; HEADACHE; HEPATITIS B; HUMAN; HUMAN TISSUE; ISHAK FIBROSIS SCORE; LEUKOPENIA; LIVER FIBROSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEROCONVERSION; SIDE EFFECT; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT RESPONSE; TRICHOMADESIS; VIRAL CLEARANCE; VOMITING; WEIGHT REDUCTION;

ADENINE; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CHINA; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INDIVIDUALIZED MEDICINE; INTERFERON-ALPHA; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84860508276     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge12183     Document Type: Article

References (16)

1. Hoofnagle JH, Doo E, Liang TJ, et al.: Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45:1056-1075. (Pubitemid 46646501)
2. Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2007; 45:507-539. (Pubitemid 46374607)
3. Lin SM, Yu ML, Lee CM, et al.: Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46:45-52.
4. Marcellin P, Chang TT, Lim SG, et al.: Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008; 48:750-758.
5. Yang YF, Zhao W, Zhong YD, et al.: Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat 2009; 16:265-271.
6. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
7. Lau GK, Piratvisuth T, Luo KX, et al.: Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682-2695. (Pubitemid 41007823)
8. Piratvisuth T, Lau G, Chao YC, et al.: Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int 2008; 2:102-110. (Pubitemid 351250409)
9. Leung N, Peng CY, Hann HW, et al.: Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology 2009; 49:72-79.
10. Ghany MG, Doo EC: Antiviral resistance and hepatitis B therapy. Hepatology 2009; 49:S174-184.
11. Janssen HL, van Zonneveld M, Senturk H, et al.: Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365:123-129. (Pubitemid 40091801)
12. Marcellin P, Lau GK, Bonino F, et al.: Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206-1217. (Pubitemid 39296307)
13. Marcellin P, Lada O, Asselah T: Treatment of chronic hepatitis B with the combination of pegylated interferon with lamivudine. Hepatol Res 2007; 37:S55-61. (Pubitemid 47086517)
14. Wursthorn K, Lutgehetmann M, Dandri M, et al.: Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44:675-684. (Pubitemid 44433724)
15. Piccolo P, Lenci I, Demelia L, et al.: A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 2009; 14:1165-1174.
16. Lutgehetmann M, Volzt T, Quaas A, et al.: Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. Antivir Ther 2008; 13:57-66. (Pubitemid 351541674)